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Abstract
Objectives: to measure the neurocognitive performance of recent users of 
recreational Ecstasy/MDMA, and investigated whether it was associated with the 
stress hormone cortisol.  
Methods: the 101 participants comprised 27 recent light users of Ecstasy/MDMA (1-4 
times in last 3 months), 23 recent heavier Ecstasy/MDMA users (+5 times), and 51 
non-user controls. Rivermead paragraph recall provided an objective measure for 
immediate and delayed recall. The Prospective and Retrospective Memory 
Questionnaire provided a subjective index of memory deficits. Cortisol levels were 
taken from near-scalp 3-month hair samples.
Results: Cortisol was significantly raised in recent heavy Ecstasy/MDMA users 
compared to  controls, whereas hair cortisol in recent light Ecstasy/MDMA users was 
not raised. However both Ecstasy/MDMA groups were significantly impaired on the 
Rivermead delayed word recall, and both groups reported significantly more 
retrospective and prospective memory problems. Stepwise regression confirmed that 
lifetime Ecstasy/MDMA predicted the extent of these memory deficits. There were no 
significant correlations between hair cortisol over the past 3 months, and the memory 
measures. 
Conclusions: recreational Ecstasy/MDMA is associated with increased levels of the 
bio-energetic stress hormone cortisol, and significant memory impairments. However 
there was no significant relationship between the neurohormonal levels and the 
cognitive deficits. 
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The ring-substituted methamphetamine derivative MDMA or ‘Ecstasy’ is a 
powerful central nervous system (CNS) stimulant, that stimulates serotonin (5-
hydroxytryptamine, 5-HT) release through indirect agonistic actions on the 
serotonergic system. MDMA (3.4-methlenedioxymethaphetamine) has been 
described as neurochemically messy, since it also affects several other 
neurotransmitters, including dopamine, noradrenaline and histamine (Green et al, 
2003; Ricaurte et al, 2000). MDMA is known for its euphoric and entactogenic 
properties, since it can induce subjective feelings of happiness and closeness to 
others (Parrott, 2001, 2007; McCann et al, 2007; Taurah et al, 2013). The 
recreational use of Ecstasy/MDMA  is associated with a range of 
neuropsychobiological problems, in memory and higher cognition (Parrott, 2001, 
2013a,b; Rendell et al, 2007; Murphy et al, 2009; Piechatzek et al, 2009), 
neurohormonal activity (Gerra et al, 2003; Parrott, 2009), psychiatric well-being (Bedi 
et al, 2010; Karlsen et al, 2008; Potter et al, 2013; Roiser & Sahakian, 2004; Soar et 
al, 2004; Wallinga et al, 2009; Taurah et al, 2013), mood state (Curran & Travill, 
1997; Hoshi et al, 2006; Parrott et al., 2011; Scott et al, 2013), pain sensitivity 
(McCann et al., 2011), sleep (Blagrove et al., 2011; Carhart-Harris et al, 2009; 
McCann & Ricaurte, 2007; McCann et al, 2009), and psychomotor ability (Dastrup et 
al, 2010; Parrott & Lasky, 1998; Rizzo et al, 2005; Verkes et al, 2001; Wilson et al, in 
press). Furthermore, in many of these psychobiologial areas the degree of 
impairment is associated with lifetime Ecstasy/MDMA usage (Parrott et al, 2000; 
Roderique-Davies & Shearer, 2010; Soar et al, 2006; Sterk et al, 2007). 
Over the past 25 years, research into Ecstasy/MDMA has attempted to 
identify the mechanisms through which it causes these neuropsychobiological 
changes. Neuroimaging studies on 5-HT markers in recreational ecstasy/MDMA 
users have identified reduced levels of the 5-HT transporter (SERT) in many brain 
areas. For instance, serotonergic damage has been identified in the frontal cortex, 
which is involved with impulsivity and higher cognition, while the hippocampus is 
closely involved in memory (Benningfield & Cowan, 2013; McCann & Ricaurte, 2003; 
McCann et al., 2005; Murphy et al, 2009; Kish et al, 2010; Parrott, 2012a; Roberts et 
al, 2013). Ecstasy/MDMA can also influence  neuroendocrine activity, both acutely 
and chronically (Dumont & Verkes, 2006; Parrott, 2009). An acute dose has 
stimulatory effects on the hypothalamic-pituitary-adrenal (HPA) axis, leading to 
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increased secretion of the glucocorticoid hormone cortisol (Harris et al, 2002; see 
also Dumont & Verkes, 2006; Kuypers et al, 2013). In laboratory studies acute 
MDMA leads to a cortisol increase of 100-200% in sedentary humans, depending on 
factors such as dosage (Harris et al, 2002; Kuypers et al, 2013), and single or 
closely-repeated administration (Farre et al, 2004). Even greater neurohormonal 
changes have been found in real world studies of recreational users, with self-
administered Ecstasy/MDMA by dance clubbers leading to an increase in salivary 
cortisol of around 800% (Parrott et al, 2013; Parrott et al, 2008). This larger increase 
is hypothesised to result from the combination of drug and environmental stimulation, 
since dance clubs involve loud music, dense crowding, and prolonged periods of 
dancing. These environmental factors have been incorporated into the bio-energetic 
stress model, attempts to explain the variability in neuropsychological, functional and 
structural consequences of recreational Ecstasy/MDMA (Parrott, 2001, 2009, 2013a; 
Parrott et al, 2006). 
Corticosteroids are essential for normal brain functioning, and are involved in  
neuro-adaptive responses to environmental changes; furthermore low or high levels 
of corticosteroids can be damaging to various psychobiological functions (Herbert et 
al, 2006).  The exposure to repeated stressors, such as Ecstasy/MDMA consumption 
in biologically stressful situations, may increase cortisol levels, and can be a 
contributory factor for any associated neurocognitive effects (Parrott et al, 2006, 
2008). Wetherell and Montgomery (2014) reported significantly greater levels of 
anxiety and depression, and elevated diurnal cortisol profiles, in abstinent 
Ecstasy/MDMA users. As noted earlier, recreational Ecstasy/MDMA use is 
associated with memory problems and other neurocognitive deficits (Parrott et al, 
1998; Gouzoulis-Mayfrank et al., 2000; Rendel et al, 2007; Parrott, 2013a,b; Meyer, 
2013). Structural damage to brains areas related to memory function, including the 
fronto-temporal and hippocampal regions (McEwen, 2005), have been observed to 
be altered in Ecstasy/MDMA users, and this damage may partially reflect a repeated 
exposure to high levels of cortisol. Further to this, heavy users of Ecstasy/MDMA can 
display significant neuroendocrine changes in comparison to controls and lesser 
users of Ecstasy/MDMA - in the form of reduced cortisol response to serotonin 
agonists (Gerra et al, 2000; Verkes et al, 2001). As such, the repeated exposure to 
high levels of cortisol through Ecstasy/MDMA exposure may constitute a potential 
mechanism for the associated memory impairments detected in Ecstasy/MDMA 
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users (Parrott, 2009). 
Kuypers et al (2012) investigated this hypothesis by giving participants a 
cortisol synthesis inhibitor (metyrapone), together with a single dose of MDMA. They 
reported that the cortisol inhibiting effect of metyrapone did not prevent the MDMA-
induced verbal memory impairment; this allowed them to conclude that the cortisol 
response to MDMA was unrelated to the memory deficits. However this was a single 
does study, and the effects of repeated Ecstasy/MDMA use on cortisol and cognition 
remain unclear. The bio-energetic stress model predicts that repeated drug usage 
will lead to chronically increased levels of cortisol (Parrott, 2006, 2009). Furthermore, 
any basal neurohormonal changes may have adverse practical implications, given 
the importance of cortisol for homeostasis, neurocognition, and psychobiological 
integrity (Herbert et al., 2006). Initial evidence suggests that drug-free Ecstasy users 
exhibit altered baseline cortisol, also stress-responsive cortisol secretion (Gerra et 
al., 2003). Although some equivocal evidence exists concerning the longer term 
endocrine changes associated with Ecstasy/MDMA usage. For example, Allott et al 
(2009) observed no persistent effect of MDMA use on neuroendocrine functioning 
with respect to a serotonergic challenge study, with Ecstasy/Polydrug, 
Cannabis/Polydrug and Non-drug using controls not differing in their cortisol 
responses to citalopram. Whereas, Wolff and colleagues examined cortisol samples 
‘in the field’ in participants pre- and post-clubbing (Wolff et al, 2012). They observed 
changes in cortisol readings to be significantly greater in MDMA-positive clubbers, 
and that these changes were related to the low activity catechol-O-methyl 
transferase  genotype. They concluded that chronic use of MDMA may lead to HPA 
axis dysregulation, although this may be moderated by genetic polymorphism. 
Frokjaer et al (2013), demonstrated an empirical link between cortisol  and prefrontal 
serotonin, hence supporting the putative links between elevated cortisol, 
serotonergic neurotoxicity, and disrupted memory  (McCann et al, 2008; Kish et al, 
2010; Parrott, 2006, 2013b). 
Until recently, the measurement of cortisol levels has been limited to biological 
markers, such as blood, saliva, or urine samples, taken at single time points. Since 
cortisol is a labile hormone, these measures may be influenced by situational factors 
and circadian activity (Hellhammer et al, 2007; Stalder et al, 2009). The assessment 
of cortisol in hair comprises an important methodological advance, since it provides a 
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single index of neurohormonal level over several months (Stalder & Kirschbaum, 
2012). In the current study we utilized this novel procedure to investigate the link 
between recent Ecstasy/MDMA use, and the amount of cortisol deposited in hair 
over the previous 3-months. The basic findings of significantly higher cortisol in 
heavier Ecstasy/MDMA users, have been fully described elsewhere (Parrott et al, 
2014).  In the current report, we present the memory test findings from that study, 
and analyse the relationship between the cognitive changes and cortisol levels. We 
compare the same three groups of light recent MDMA users, heavy recent MDMA 
users, and non-user controls (Parrott et al, 2014). The first hypothesis was that 
memory  performance would be impaired in the recreational Ecstasy/MDMA users. 
Secondly, we hypothesized that the extent of memory impairment would be greater 
in those participants with higher levels of hair cortisol.     
Methods
Participant characteristics
One-hundred and one participants (53 males, 48 females, mean ± SD age: 21.75 ± 
4.23 years) were recruited via advertisements concerning MDMA usage. Study 
inclusion was restricted to participants who had hair longer than 3cm at the posterior 
vertex region of the scalp, and who did not suffer from any chronic medical or 
psychiatric conditions. Participants were divided into three subgroups depending on 
their self-reported Ecstasy/MDMA usage over the prior three months. Recent light 
users comprised 27 participants (18 male, 9 female, mean ± SD age: 21.15 ± 1.09 
years) who had consumed MDMA between one and four times in the past 3-months. 
Recent heavy users comprised 23 participants (7 male (one participant was removed 
due to multiple outliers across demographic and outcome measures), 15 female, 
mean ± SD age: 21.48 ± 0.89 years) who had consumed MDMA five or more times 
in the past 3-months. The control group comprised 51 individuals (27 male, 24 
female, mean ± SD age: 21.20 ± 5.85 years) who had not consumed any MDMA in 
the past 3-months. The drug usage characteristics for the three subgroups are given 
in Table 1. Written informed consent was provided by all participants. The sign-up 
form indicated that the University did not condone the use of illicit substances, and 
provided sources of information for advice on drug related problems. The study was 
conducted in accordance with the Declaration of Helsinki, and was approved by the 
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University ethics committee, and the participants were not compensated for their 
participation. 
- Table 1 near here -
Assessment measures  
Demographic and hair-related variables. A self-developed questionnaire was used to 
record socio-demographic and lifestyle variables, such as sex and age, in addition 
hair-related characteristics, such as hair colour, washes per week, and hair 
treatments were assessed (as in Stalder et al, 2012).
Recreational Drug Use Questionnaire. This self-rating questionnaire covered 
recreational drug-usage during the previous 3-months (Parrott et al, 2001). It 
covered all the main types of drug, both legal (alcohol, tobacco/nicotine), and illegal 
(cannabis, Ecstasy/MDMA, amphetamine, cocaine, and others; see Table 1).  We 
also covered lifetime usage for the illicit drugs (Table 4).  
 
Hair cortisol. Hair strands (~3 mm diameter) were carefully cut as close as possible 
to the scalp from the posterior vertex region at the back of the head. The scalp-near 
3 cm hair segment was used for analyses. Based on a hair growth rate of 
~1cm/month (Wennig, 2000), this segment reflects hair grown over the previous 
three months. Wash and steroid extraction procedures followed the laboratory 
protocol described previously (Stalder & et al, 2012b, study II) with 10 mg of whole, 
non-pulverised hair being used for analyses. After extraction, cortisol concentrations 
were determined using a commercially available immunoassay with 
chemiluminescence detection (CLIA, IBL-Hamburg, Germany) in the Biopsychology 
Laboratory, University of Dresden, Germany (Professor Clemens Kirschbaum). Intra-
assay and inter-assay coefficients of variation of this assay are below 8%.
Objective Memory. The Rivermead Behavioural Memory Test (Wilson, Cockburn, 
Baddeley, & Hiorns, 1989) involved the reading of two paragraphs, containing 60/61 
words and 21 key ideas each. One paragraph was to be recalled immediately 
whereas the other was to be recalled following a 5 minute delay, in which Trail-
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making Test B was administered as a distractor task (Mitrushina, 2005). The 
standardised scoring was for total ideas correctly recalled.  
Subjective Memory. The Prospective and Retrospective Memory 
Questionnaire (Crawford, Smith, Maylor, Della Sala, & Logie, 2003) comprised 16 
questions - 8 questions covering prospective memory and 8 related to retrospective 
memory. Reponses were evaluated on the following forced-choice scale:  never = 1, 
rarely = 2, sometimes = 3, quite often = 4, very often = 5.  
Design and procedures.
The unpaid volunteer subjects were ….
Results
Cortisol
Group mean cortisol values are presented in Table 2. The between-group ANOVA 
showed that non-user controls had the lowest group mean cortisol values, and these 
were marginally higher (non-significantly) in recent light Ecstasy/MDMA users. 
Recent heavy Ecstasy/MDMA users had cortisol values significantly higher (by 
around 400%) that non-user controls (p<0.001), and significantly higher (by around 
300%) than recent light users (p<0.001). The cortisol findings are described more 
fully in Parrott et al (2014).  
Objective and Subjective Memory
Means and standard deviations of both objective and subjective memory measures 
are displayed in Table 2. A higher score on the Objective Memory tasks indicates 
better recall performance, whereas a higher score on the subjective memory tasks 
indicates higher self-reported memory problems. Pearson’s correlation coefficients 
between each of these measures and cortisol levels are also displayed; the 
emergent correlations were all non-significant. The assessment of possible 
curvilinear relationships between cortisol levels and memory scores also yielded 
non-significant results.  A multivariate analysis of variance (MANOVA) revealed a 
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significant effect of recent Ecstasy/MDMA use on recall (F (4, 212) = 3.07, p < .05, 
çp² = .06). Univariate tests of between subject effects demonstrated a non-significant 
group effect for immediate recall (F (2, 106) = .21, p > .05, ns), but a significant  
group effect with delayed recall (F (2, 106) = 5.51, p < .01, çp² = .10). Comparison 
tests using Tukey HSD revealed significant differences between the control group 
and recent Ecstasy/MDMA light users (p < .01), and the control group and recent 
heavy Ecstasy/MDMA users (p = .01), with no significant differences between the 
two Ecstasy/MDMA subgroups.
- Table 2 near here -
The Retrospective and Prospective Memory Questionnaire revealed a 
significant MANOVA effect across the three drug groups (F (4, 212) = 4.71, p < .01, 
çp² = .08). There were also significant differences between drug groups, for the 
prospective memory subscale (F (2, 106) = 8.37, p < .01, çp² = .14), and for 
retrospective memory (F (2, 106) = 9.36, p < .01, çp² = .15). For self-reported 
prospective memory, Tukey comparison tests revealed significantly more problems 
in recent light Ecstasy/MDMA users than the control group (p < .01), and significantly 
more memory problems in recent heavy Ecstasy/MDMA users than controls (p < 
.01); there were however no significant differences between light and heavy 
Ecstasy/MDMA user groups (Table 2). A similar pattern emerged with self-reported 
retrospective memory problems. The recent light Ecstasy/MDMA users reported 
significantly more retrospective memory problems than the control group (p < .01), 
while recent heavy Ecstasy/MDMA users also noted significantly more memory 
problems than controls (p < .01); again  there were no significant differences in 
retrospective memory between the two Ecstasy subgroups.
For the three month drug data, a series of  stepwise regressions were 
undertaken to determine which drug type, or combination of drug types, predicted 
the memory deficits and cortisol values  (Table 3). High collinearity and low usage of 
certain drug types lead to their exclusion from the regression model. Six variables 
were entered into the stepwise regression – MDMA, cocaine (nasal), mephedrone, 
tobacco, alcohol,  and cannabis. The regression concerning cortisol levels identified 
two significant predictors, recent cannabis usage and recent Ecstasy/MDMA usage. 
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For the objective memory assessments, alcohol consumption was the only 
significant predictor of immediate recall (4%), and recent Ecstasy/MDMA and 
mephedrone consumption significantly predicted delayed recall performance (9%). 
For prospective memory, there were three significant predictors, recent 
Ecstasy/MDMA, tobacco, and alcohol (Table 3). For self-rated retrospective memory, 
there were  three significant predictors, recent tobacco, recent Ecstasy/MDMA, and 
recent alcohol (Table 3).  Stepwise regression analyses were then repeated with the 
lifetime usage data - for the same six drugs (Table 5). Cortisol levels were predicted 
by lifetime cannabis usage, while immediate recall was predicted by lifetime alcohol 
consumption. Delayed recall was predicted by lifetime Ecstasy/MDMA,  while 
prospective memory was also predicted by lifetime Ecstasy/MDMA. Self-rated 
retrospective memory was statistically predicted by lifetime Ecstasy/MDMA, and 
lifetime alcohol (Table 5).   
- Tables 3, 4, 5 near here -
Discussion
This study confirmed the adverse effects of recreational Ecstasy/MDMA on objective 
memory task performance, and self-reported memory deficits. On the Rivermead 
delayed recall performance test, both groups of recent Ecstasy/MDMA users were 
significantly impaired, in comparison with non-user controls (Table 2). A similar 
pattern of deficits was found with the Retrospective and Prospective Memory 
Questionnaire, where both groups of Ecstasy/MDMA users reported significantly 
more memory problems, than the control group (Table 2). The contributory role of 
Ecstasy/MDMA was statistically confirmed in the regression analyses. When recent 
3-month drug usage was considered, Ecstasy/MDMA was found to be a significant 
predictor for delayed word recall, for prospective memory problems, and 
retrospective memory problems (Table 3). When the lifetime drug usage values were 
entered into the regression analysis, lifetime Ecstasy/MDMA consumption was a 
significant predictor for delayed word recall, the prospective memory questionnaire 
deficits, also the retrospective memory questionnaire deficits  (Table 4). The findings 
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were consistent  with the extensive empirical literature on memory  deficits in 
abstinent Ecstasy/MDMA users (Krystal et al, 1992; Bolla et al 1998; Parrott et al, 
1998; Parrott and Lasky, 1998; Verkes et al, 2001; Fox et al, 2001, 2002; Laws and 
Kokkalis, 2007; Rogers et al, 2009; Taurah et al, 2013). However not every study 
has found deficits (Parrott, 2006, 2013b; Rogers et al, 2009), and this was confirmed 
here, since there were no group differences in immediate word recall (Table 2).  The 
presence of deficits in delayed recall, but not in  immediate recall, suggests that time 
may be important factor – with Ecstasy/MDMA putatively affecting the key process of 
information storage.  
The second aim of the current study was to examine whether hair cortisol levels 
would be related to neurocognitive performance. As previously reported (Parrott et 
al, 2014), the only significant group differences in cortisol hair deposits, was found in 
the recent heavy Ecstasy/MDMA user group. Yet both groups of Ecstasy/MDMA 
users showed significant memory deficits – recent heavy users, and recent light 
users (Table 2). Hence there was a general dissociation between the neurohormonal 
and the neurocognitive findings. The independence of the cortisol and cognitive 
findings, was statistically confirmed in their near zero correlations. Hence for 
immediate word recall, delayed word recall, retrospective memory, and prospective 
memory, the 3-month hair cortisol values did not correlate with any memory test 
score (Table 2).  This clearly suggests that the neurocognitive and neurohormonal 
effects of recreational MDMA are independent. However there may be other 
potential reasons for the lack of any statistical associations here. Firstly, the cortisol  
values covered the previous three months, whereas the cognitive deficits would be 
primarily related to lifetime usage. Furthermore,  longer-term Ecstasy/MDMA users 
tend to use the drug less frequently than novice users (Parrott, 2005), so that the 
light current user subgroup may have contained a number of heavy lifetime users. 
Gerra et al (2003) found that cortisol levels returned to baseline after 12 months of 
abstinence. Whereas the cognitive performance of ecstasy users tends to remain 
impaired for a period of time after cessation (Morgan et al, 2002; Taurah et al, 2013).  
The regression analyses identified recent cannabis and recent 
Ecstasy/MDMA usage as significant predictors of cortisol levels (R2 = 21%), with 
higher consumption of each drug being related to the increased cortisol deposits 
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(Table 2). Previous research has shown that acute cannabis consumption 
(Ranganathan et al., 2009), and acute Ecstasy/MDMA consumption (Kuypers et al., 
2013), can increase cortisol secretion. Furthermore the adverse neurocognitive and 
neuropsychiatric sequelae of chronic cannabis (King et al., 2011), and chronic 
recreational Ecstasy/MDMA (Parrott, 2009, 2013b), have been suggested to be 
partially mediated through their effects on cortisol. Heavy recreational use of 
cannabis is associated with executive function deficits, in attentional impairments 
and reduced mental flexibility  (Lindquist, 2010). In a similar fashion, repeated 
Ecstasy/MDMA usage may lead to neurocognitive difficulties - in encoding memories 
for long-term retrieval, verbal learning, and reduced attentional control of higher 
cognitive processing (Lindquist, 2010). Deficits in this constellation of cognitive 
components due to MDMA and/or cannabis usage may have negative impacts upon 
daily functioning, and may be accompanied by alterations in neuroendocrine 
integrity.  Although a significant relationship was not observed between the levels of 
accumulated cortisol over three months, and Ecstasy/MDMA usage (Table 3. Hence 
other mechanisms and patterns of licit/illicit drug usage, may be contributing to both 
the disruptions in memory performance, and the changes in neuroendocrine activity. 
In relation to recent drug use, Ecstasy/MDMA consumption was found to be 
the strongest predictor of variation in delayed recall performance (along with 
mephedrone consumption), self-rated prospective memory (with tobacco use and 
alcohol consumption), and the second strongest predictor of self-rated retrospective 
memory behind tobacco usage (Table 3). Lifetime drug use was also associated with 
the neurocognitive and neurohormonal changes (Table 5). These findings are 
consistent with previous findings that have illustrated the metabolic deficiencies in 
brain areas implicated in working memory and lifetime dosage studies of 
Ecstasy/MDMA users (Benningfield & Cowan, 2013; Gouzoulis-Mayfrank et al., 
2000; Sterk et al., 2007; Verdejo-García, López-Torrecillas, Aguilar De Arcos, & 
Pérez-García, 2005). Given the participants in this study also consumed alcohol, 
tobacco, and various illicit drugs in addition to Ecstasy/MDMA, and the drug usage 
amounts are based upon self-reporting, the results still need to be interpreted with 
some caution. The regression analyses also only included six of the drug types that 
were sampled (given the low usage of some drugs, and high collinearity of the usage 
pattern of the lesser used drugs). Whilst these other drugs may have additive or 
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synergistic effects upon both the psychological and physiological outcomes utilized 
in this study, it is beyond the scope of this study to attribute their effects. 
This leads into another ubiquitous limitation of these types of cross-sectional 
design studies, where estimates of retrospective drug use may be considered 
unreliable. Also we were unable to confirm ‘recent’ use of the target drug types 
through biological sampling, therefore again relied upon accurate reporting of drug 
use, and that the declared drugs were what the participants believed they had 
consumed. With regard to assessment of cortisol, whilst the accumulated deposits of 
cortisol in the hair over the three month sampling period offer some insight into 
‘recent’ stress, it cannot be causatively linked to on-going memory deficits of the 
MDMA using groups in this study. Future study designs could consider a more 
longitudinal approach to assessing changes in memory performance in alongside 
hair cortisol changes, or consider changes in HPA functionality through daily cortisol 
profiling,  as employed by Wetherell and Montgomery (2014). It is also important to 
empirically investigate how the different measures of cortisol (saliva, blood, hair) may 
be interrelated. While future studies should also include subjective indices for self-
rated anxiety or stress. 
Further research is also needed to examine the additive or synergistic actions 
of licit and illicit drugs upon multiple mechanisms underlie the cellular adaptations, 
dysfunction, and neurotoxic or neuroprotective nature of stimulants and other 
substances of abuse. Use of these substances has been observed to lead to the 
variable levels of neurocognitive and psychiatric dysfunction (Downey & Loftis, 
2014), and it is an important research question to ascertain just how much of certain 
drugs alone or in combination can be consumed before irreparable damage to the 
brain is done. It is also likely that a wide range of factors influence synergize with the 
effects of substances of abuse to impact brain and neuroendocrine function, thus 
qualifying the molecular changes within the brain and endocrine system with respect 
to exposure to specifically abused substances like Ecstasy/MDMA, should inform the 
development of therapeutic approaches to addiction and symptoms of heavy usage.   
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Table 1 Recreational drug use over the past 3 months: (group means and standard 
deviations), from a modified version of the University of East London Recreational Drug Use 
Questionnaire (Parrott et al, 2001). 














MDMA 0 0 (0) 31 2.74 (1.13)** 23 7.57 (2.41)**
Amphetamine 1 1 (0) 7 5 (4.97)* 1 3 (0)
Cocaine (Nasal) 2 5.50 (6.36) 12 9.42 (16.57)* 11 1.91 (1.22)
Cocaine (Crack) 0 0 (0) 0 0 (0) 0 0 (0)
LSD 1 1 (0) 1 1 (0) 1 1 (0)
Mephedrone 7 8.43 (6.61) 12 11.58 (16.97) 6 1.5 (0.84)
Opiate 0 0 (0) 0 0 (0) 1 1 (0)
Barbiturate 1 3 (0) 2 1.5 (0.71) 2 3.5 (3.54)
Magic 
Mushrooms 0 0 (0) 1 1 (0) 1 1 (0)
Steroids 0 0 (0) 0 0 (0) 0 0 (0)
Solvents 0 0 (0) 0 0 (0) 0 0 (0)
Poppers 1 3 (0) 2 1 (0) 4 1 (0)
Ketamine 0 0 (0) 2 3 (2.83) 2 1.5 (0.71)
Tobacco 
(Cigarettes Daily) 19 7.53 (4.71) 26 6.54 (3.77)* 13 6.62 (4.46)
Alcohol
(Units Weekly) 51 14.28 (11.71) 31 20.39 (12.41)* 23 19.70 (9.8)
Cannabis 
(Uses Monthly) 20 7.30  (10.97) 26 15.19 (11.56)** 18 11.07 (12.11)
** Tukey HSD – Significantly different from control group at p<0.01 level
* Tukey HSD – Significantly different from control group at p<0.05 level
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Table 2 Cortisol levels from three month hair samples, memory recall performance, and self-rated 
memory problems (means and standard deviations). Correlations between the hair cortisol 



















(total correcct) 7.59 3.04 6.03 2.70 7.09 3.63 -0.04 >.05
Delayed Recall 
(total correct) 6.83 3.49 4.19** 3.28 4.91* 1.98 -0.16 >.05
Prospective Memory 
(problems) 20.50 5.99 24.32** 4.64 24.30** 3.99 0.01 >.05
Retrospective 
Memory (problems) 18.26 5.76 21.81** 4.62 22.26** 4.59 0.12 >.05
** Tukey HSD – Significantly different from control group at p<0.01 level
* Tukey HSD – Significantly different from control group at p<0.05 level
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Table 3 Stepwise Regression of recent 3-month drug usage upon cortisol levels and objective and 
subjective memory assessments
Step Variable Beta t Adjusted R²
Cortisol 1 Cannabis 0.359 3.81** 0.12
2 Cannabis 0.306 3.35**
  MDMA 0.300 3.29** 0.20
Immediate 
Recall 1 Alcohol 0.223 2.36* 0.04
Delayed
Recall 1 MDMA -0.257 -2.73** 0.06
2 MDMA -0.248 -2.69**
  Mephedrone -0.213 -2.31* 0.09
Prospective 
Memory 1 MDMA 0.344 3.78** 0.11
2 MDMA 0.299 3.34**
Tobacco 0.260 2.91** 0.17
3 MDMA 0.259 2.87**
Tobacco 0.255 2.89**
  Alcohol 0.185 2.08* 0.19
Retrospective 
Memory 1 Tobacco 0.338 3.69** 0.11
2 Tobacco 0.291 3.25**
MDMA 0.264 2.94** 0.17
3 Tobacco 0.286 3.24**
MDMA 0.223 2.47*
  Alcohol 0.188 2.11* 0.19
**Significant at the p<0.01 level
* Significant at the p<0.05 level
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Table 4 Lifetime use of illicit drugs (UEL Recreational Drugs Questionnaire, Parrott et al, 
2001).
** Tukey HSD – Significantly different from control group at p<0.01 level






Mean Times Used (SD) Mean Times Used (SD) Mean Times Used (SD)
MDMA 4.41 (12.08) 21.06 (25.19)** 34.74 (26.44)**
Amphetamine 0.37 (1.51) 7.87 (20.19)* 2.87 (5.67)*
Cocaine (Nasal) 7.87 (29.77) 23.55 (44.05) 7.78 (8.82)
Cocaine (Crack) 0.00 (0.00) 0.03 (0.17) 0.00 (0.00)
LSD 0.20 (1.37) 0.26 (0.77) 1.43 (3.68)*
Mephedrone 12.59 (39.29) 28.48 (57.95) 5.22 (5.22)
Opiate 0.09 (0.49) 0.10 (0.40) 0.17 (0.39)
Barbiturate 1.20 (6.92) 1.87 (5.80) 0.65 (2.16)
Magic 
Mushrooms
0.44 (1.66) 1.26 (1.88) 2.78 (5.44)*
Steroids 0.02 (0.02) 0.00 (0.00 0.00 (0.00)
Solvents 0.46 (2.75) 0.00 (0.00) 0.13 (0.63)
Poppers 2.15 (8.54) 4.87 (18.01) 5.13 (11.03)
Ketamine 2.39 (13.68) 3.00 (7.82) 1.87 (4.57)
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Table 5 Stepwise Regression of lifetime drug usage upon cortisol levels and objective and 
subjective memory assessments
Step Variable Beta t Adjusted R²
Cortisol 1 Cannabis 0.292 3.02** 0.12
 
Immediate 
Recall 1 Alcohol 0.223 2.36* 0.04
Delayed
Recall 1 MDMA -0.230 -2.44* 0.04
Prospective 
Memory 1 MDMA 0.398 3.46** 0.15
Retrospective 
Memory 1 MDMA 0.300 3.24** 0.08
2 MDMA 0.255 2.72**
Alcohol 0.199 2.12* 0.11
**Significant at the p<0.01 level
* Significant at the p<0.05 level
